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Abstract
Background: Rotavirus (RV) vaccine was added to Yemen’s childhood vaccination schedule in late 2012. We evaluated
the effect of vaccination on the epidemiology of acute gastroenteritis (AGE) and the characteristics of circulating RV
strains.
Methods: Surveillance data was obtained at two sentinel hospitals from 5,691 children with acute gastroenteritis (AGE)
who were under 5 years of age. Data collected before (2007–2011) and after (2013–2014) RV vaccine introduction were
retrospectively analyzed. Treatment outcome, presence of severe dehydration, and the proportion of all-cause AGE due
to RV-antigen positive AGE were calculated for each period and compared. Binominal generalized linear models were
used to calculate adjusted odds ratios (ORs) and 95 % confidence intervals (CIs). We also compared severe RVAGE and
severe dehydration proportions in hospitalized children with severe AGE and characterized RV circulating strains in
available specimens from the two periods.
Results: Before RV vaccination, mean RVAGE prevalence peaked in October (58.8 %), November (69.5 %), and
December (56.4 %). In 2013–2014, the variation became less defined, with only a few RVAGE cases. The average annual
prevalence of severe RVAGE needing hospitalization was 42.9 % in 2007–2011, decreased to 21.1 % in 2013, and to
18.5 % in 2014, representing declines of 50.8 % (95 % CI: 36.4–65.0) and 56.9 % (95 % CI: 42.1–70.5). The proportion of
children <12 months of age with all-cause AGE decreased significantly after introduction of RV vaccination (58.7 % vs.
62.3 %; p = 0.042), severe dehydration decreased by 50 % (14.7 % vs. 21.7 %; OR = 0.501, p < 0.0001), and RVAGE
proportion decreased by 48 % (19.9 % vs. 41.6 %; OR = 0.52, p < 0.0001). The proportion of severe RVAGE in hospitalized
patients decreased by 67 % (20.1 % vs. 43.5 %; OR = 0.33, p < 0.0001), and severe dehydration decreased by 58 %
(17.2 % vs. 33.1 %; OR = 0.42, p < 0.0001). Non-RV AGE prevalence significantly increased, with ORs of 2.8–3.1 in favor of
non-RV AGE in 2013–2014. Analysis of 128 available stool specimens revealed that circulation of the G1 genotype did
not change following vaccination (33.3 % vs. 41.3 %; p = 0.366). G2 significantly decreased in 2013–2014 (4.2 % vs.
42.5 % p = 0.0001), and G9 increased (29.2 % vs. 6.3 %; p = 0.001). G1P[8] and G2P[4] remained prevalent, and G9P[8]
and G9P[4], which were not detected in the pre-vaccine period appeared in 2013–2014. G and [P] mixed genotypes
became more prevalent in 2013–2014. It is not known if this predominance is related to the vaccine introduction or
attributable to normal genotype fluctuations.
(Continued on next page)
* Correspondence: salembanaj@gmail.com
1Faculty of Medicine & Health Sciences, Sana’a University, Sana’a, Yemen
Full list of author information is available at the end of the article
© 2015 Banajeh and Abu-Asba. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Banajeh and Abu-Asba BMC Infectious Diseases  (2015) 15:418 
DOI 10.1186/s12879-015-1165-8
(Continued from previous page)
Conclusions: Rotarix substantially reduced the prevalence of RVAGE, with a 67 % reduction of severe RVAGE
hospitalizations, and over 50 % reduction of diarrhea with severe dehydration. Circulation of RV G and [P] mix strains
was significantly increased in 2013–2014 and needs continuous monitoring.
Keywords: Rotavirus vaccine, Severe rotavirus hospitalization, Severe dehydrating diarrhea, Rotavirus strains, Yemen
Background
In developing countries, diarrhea remains one of the
most frequent causes of death among children under
5 years of age. Rotavirus (RV) is the most common cause
of severe diarrhea in infants and young children and the
major cause of diarrhea-related child mortality. It
accounts for more than 2 million hospital admissions
annually [1–3]. The World Health Organization (WHO)
recommends the introduction of rotavirus vaccine in
national immunization programs especially in develop-
ing countries with high childhood mortality [4, 5].
Yemen is one of the least developed countries and is the
only low-income country in the Arabian Peninsula. It
has a population of 25.2 million, 16.1 % of whom are
under 5 years of age. Health information published in
2014 by the WHO estimates that 47 % of children in
Yemen under 5 years of age are stunted and 16 % are
wasted [6]. The data also indicates that only 27.8 % of
children who developed diarrhea received oral rehydra-
tion therapy and estimates infant and under 5-year mor-
tality rates are 40.4 and 51.3 per 1000 live births,
respectively [6].
Acute gastroenteritis (AGE)-related morbidity and
mortality is a major health problem in Yemen. A recent
report on the global, regional, and national causes of
child mortality estimated that in 2013, 16.8 % of 19 607
deaths from all causes in children 1–59 months of age
was diarrhea related. The corresponding estimate for
2007 was 21.2 % of 26,800 deaths, indicating a reduction
of only 4.4 % over a 7-year period [7]. Data on the bur-
den of rotavirus acute gastroenteritis (RAVGE) in Yemen
are scarce. Only one hospital-based study was published
before the introduction of rotavirus vaccine, In that
study, Kirby et al. reported that 27 % of children from 1
to 5 years of age who were treated for AGE in the emer-
gency and outpatient departments of two hospitals in
Sana’a had rotavirus, and 10 % had norovirus infections
[8]. However, the study was limited by its geographical
restriction to one city located in the northern highlands
region of Yemen.
There were three study objectives. The first was to
examine trends in the annual prevalence of RVAGE in
children hospitalized with severe AGE. The second was
to compare the proportions of RVAGE, WHO-defined
severe dehydration, and the treatment outcomes of chil-
dren younger than 5 years of age who were treated for
all-cause AGE at the sentinel hospitals or were hospital-
ized with severe dehydrating diarrhea. The third was to
assess and examine the prevalence, characteristics and
diversity of the circulating rotavirus strains, before and
after introduction of RV vaccine in Yemen’s national
immunization program.
Methods
In 2004, the Ministry of Public Health in Yemen imple-
mented surveillance of AGE (including RVGE) in chil-
dren less than 5 years of age at sentinel hospitals. The
surveillance unit is supported technically and financially
by the WHO Eastern Mediterranean Regional Office
(EMRO), which includes surveillance training for hos-
pital staff. The standard operating procedures (SOPs)
used by the Rotavirus gastroenteritis surveillance net-
work in the EM Region are described in the WHO gen-
eric protocol for rotavirus surveillance [9].
Study sites
The study evaluated surveillance data collected from two
sentinel hospitals. The first was the Al –Sewedy hospital
located in Taiz city, serving the population of Taiz and
the surrounding rural areas. The Taiz governorate has a
population of 4 million and is located in the mountain-
ous midland region of Yemen at an altitude of 1400 m
above sea level. The second center was Al-Wehdah hos-
pital located in the southern city of Aden, which serves
a population of 1,400,000, including Aden and the adja-
cent southern governorates. Aden is located along the
coast of the Arabian Sea. Each hospital has a capacity of
more than 600 beds, walk-in outpatient units receiving
patients on work days, and 24-h emergency rooms. Sur-
veillance began at Al-Sewedy Hospital in 2007, and at
Al-Wehdah Hospital in 2008. Following the WHO–
EMRO guidelines, a trained surveillance officer at each
hospital collects information on children who visit the
hospital because of AGE and submits standard case
report forms to the surveillance unit every month. The
reports are checked for accuracy and missing data are
obtained by communication with the surveillance officer
at the sentinel hospital. Data are recorded in Microsoft
Office Excel 2007 software.
Rotarix™ vaccine (GlaxoSmithKline Biologicals, Belgium)
was introduced in the national immunization program
of Yemen in October 2012 with support from the
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Global Alliance for Vaccines Initiative (GAVI). Rotarix, is
a monovalent live attenuated human rotavirus vaccine
based on the G1P[8] strain. It is given orally as two doses
at 6 and 10 weeks of age, and is free of charge to all chil-
dren in Yemen. The national vaccination coverage rates
for the second dose of Rotarix was 23 % in 2012 and 90 %
in 2013. The coverage rates in Taiz and Aden were 25 and
30 % in 2012 and 76 and 87 % in 2013, respectively [10].
Ethical approval
The ethical review committee of the Yemen Ministry of
Public Health advised that ethical approval for this study
protocol was not needed as it was considered to be a
part of an ongoing national surveillance activity. All
study procedures constituted standard case manage-
ment. This was a retrospective analysis of data collected
from the sentinel hospitals, and patients were enrolled
only after signed informed consent had been obtained
from their parents or legal guardians. The data did
not include names of individual patients, and the au-
thors did not follow or contact the parents following
enrolment.
Study Population
Children less than 5 years who attended the sentinel
hospital outpatient unit, emergency room, and/or were
admitted as inpatients with a primary diagnosis of AGE
were included in the study after informed consent was
obtained.
Definitions
AGE (in children less than 5 years of age) was defined as
at least three watery or looser than normal stools in a
24-h period and of less than 7 days duration, and/or two
or more vomiting episodes that were unexplained by
other reasons. Dehydration status was scored as follows.
Severe dehydration (1) required two or more of the fol-
lowing signs: lethargy or unconsciousness, sunken eyes,
inability to drink, and skin pinch recovers very slowly.
Some dehydration (2) required two or more of the fol-
lowing signs: restlessness or irritability, sunken eyes,
thirst or drinking eagerly, and skin pinch goes recovers
slowly. No dehydration (3) was noted in children with
none of the above signs).
Study design
This was a retrospective observational study based on
AGE surveillance data collected prospectively during the
pre-RV vaccine period from January 2007 to December
2011, and in the post-RV vaccine period from January
2013 to December 2014. Surveillance data collected dur-
ing 2012, the year in which the RV vaccine was intro-
duced, were excluded from the analysis.
Data collection
Information on patient age (months), sex, and place of
treatment (outpatient clinic, emergency room, or
inpatient facility), plus clinical information including
duration of symptoms, diarrhea and/or vomiting (days),
the number of episodes per day before the visit, and
whether fever was present, was collected. Details of
dehydration status (severe, some, or none), treatment
given, duration of hospitalization, and treatment out-
come on discharge were also collected. Stool specimens
were obtained from children enrolled in study not later
than 7 days after the onset of the illness and within 48 h
of enrollment. Specimens were placed in labeled screw-
top containers and stored at 4 °C. Rotavirus antigen was
detected in the specimens by enzyme immunoassay
(EIA) carried out in the hospital laboratory using
WHO-approved kits (IDEIA™, DAKO Diagnostics,
United Kingdom). Rotavirus-positive specimens were
stored at −20 °C, according to SOP guidelines, until
sent to the Regional Rotavirus Reference Laboratory in
Cairo, Egypt for G and P genotyping.
Date management and statistical analysis
The surveillance data from all children included in the
study were imported from Microsoft Office Excel 2007
into SPSS software, version 20 (IBM, Armonk, NY, USA).
We used descriptive statistics to calculate the annual
prevalence of severe RVGE in children hospitalized with
all-cause severe AGE from 2007 to 2014 and the percent-
age decline in prevalence in 2013 and 2014 compared with
the average annual prevalence in the pre-vaccine years.
We also examined changes in the distribution of emer-
gency unit visits and hospitalizations for all-cause AGE
and RVGE before and after vaccine introduction by com-
paring the percentage reductions and 95 % confidence
intervals of the annual median occurrence of these events.
Pre- and post-vaccine patient characteristics were com-
pared using Pearson’s chi-square test for categorical vari-
ables and student’s-t test for continuous variables with
equal variance not assumed.
Measurement of the core study outcomes
We measured the effect of RV vaccine introduction on
all-cause AGE by comparing the proportions of patients
with severe dehydration, the prevalence of RVAGE, and
treatment outcomes (core study outcomes) obtained
during the two study periods. We used binominal gener-
alized linear models with a probit link function. The
pre- and post-vaccine periods were dependent categor-
ical variables with the post-vaccine period considered as
a response and the pre-vaccine period as the reference.
The core study outcomes were introduced separately in
the model. Each study outcome was adjusted for the fol-
lowing predictors: age, gender, duration of symptoms
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(days), number of diarrhea episodes per day, and hospital
site. The statistical procedure computed the main effect
of these cofounders expressed as an adjusted exponential
(Beta) with its 95 % Wald confidence interval (95 %
Wald CI) as well as the p value. We also compared the
proportions of patients with severe RVAGE and severe
dehydration among those hospitalized for all-cause
severe AGE, and the proportions of different RV circu-
lating strains in the pre- and post-vaccine periods. The
statistical significance level was set at p < 0.05.
Results
Surveillance data of all participants
During the study period from January 2007 to December
2014, 5691 children with all-cause AGE and under
5 years of age visited the sentinel hospitals and were
included in the analysis. Most children were young.
The mean age was 12.2 months, and 3425 (60.2 %),
were under 12 months of age. The mean duration of
symptoms, vomiting, diarrhea, and diarrhea episodes/
day were 3.1, 2.9, 3.2, and 6.4, days respectively. A
total of 2886 children (50.7 %) were hospitalized with
severe dehydrating AGE, 2308 (40.6 %) visited the
emergency room, and 479 (8.7 %) visited the out-
patient unit. Stool specimens were collected from
5495 children (96.6 %). A total of 1940 specimens
(35.3 %) were RV-antigen positive by EIA and 1210 of
those (62.4 %) were obtained from children less than
12 months of age. Stool specimens from 2747 (95.2 %)
of the 2886 children who were hospitalized with severe
AGE (n = 2886), were tested, and of those, 1005
(36.6 %) were RV positive. The annual prevalence of
hospitalized severe RVAGE remained stable with an
average of 42.9 % from 2007 to 2011. The prevalence
dropped to 21.1 % in 2013 and to 18.5 % in 2014
(Table 1); representing percentage decreases of 50.8 %
(95 % CI: 36.4–65) and 56.9 % (95 % CI: 42.1–70.5),
respectively.
Pre- and post-vaccination periods
Seasonal variation In the pre-vaccine period, the pro-
portion of children with RVAGE followed a well-defined
monthly pattern that peaked in October (58.8 %),
November (69.5 %), and December (56.4 %) and was
lowest in July (20 %), August (22.8 %), and September
(27.5 %). In the post-vaccine period, the seasonal vari-
ation became blunted and less well defined with only a
few cases of RVAGE detected (Fig. 1).
All-cause AGE Compared with the pre-vaccine period,
the proportion of children under 12 months of age with
all-cause AGE was significantly smaller in the post-
vaccine period (62.3 % vs. 58.7 %, p = 0.042), but a signifi-
cantly larger proportion presented with vomiting (88 % vs.
93.1 %; p < 0.0001) and a significantly smaller proportion
presented with fever (63.6 % vs. 45.1 %; p = <0.0001)
(Table 2). The mean ± SD duration (days) of symptoms
and of diarrhea before seeking treatment was both longer
in the post-vaccine period (2.98 ± 1.67 vs. 3.33 ± 1.58; p <
0.0001, and 3.02 ± 2.12 vs. 3.40 ± 1.89; p = 0.0001, respect-
ively). There was no significant difference in the duration
of hospital treatment (Table 2). Severe dehydration
decreased significantly from 21.7 % of children with all-
cause AGE (848/3902) in the pre-vaccine period to 14.7 %
(168/1144) in the post-vaccine period (unadjusted OR
0.64, 95 % CI: 0.54–0.77; p = 0.0001). The median annual
number of visits for all-cause AGE decreased by 26 %
(95 % CI: 23–29), from 800 in the pre-vaccine to 591 in
the post-vaccine period. Emergency room visits decreased
from 358 to 180, and hospitalizations decreased from
444 to 342, representing median reductions of 49.7 %
(95 % CI: 44.6–54.9), and 23 % (95 % CI: 19.3–27.1),
respectively.
Severe all-cause AGE
In the pre-vaccine period, 1968 children required
hospitalization for severe all-cause AGE but only 683
were hospitalized in the post-vaccine period. The
Table 1 Acute Gastroenteritis: hospitalization, NO(%) of cases that have stools tested for RV antigen and annual prevalence of severe
RVAGE from 2007 to 2014
Year of study AGE hospitalization Cases stool tested Cases positive RV + ve % Annual prevalence
N N (%) (RVGE)
2007 480 480 (100) 210 43.8
2008 239 239 (100) 104 43.5
2009 441 382 (86.6) 198 51.8
2010 514 465 (90.5) 194 41.7
2011 288 269 (93.4) 90 33.5
2012 236 236 (100) 73 30.9
2013 421 417 (99) 88 21.1
2014 264 259 (98) 48 18.5
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percentage of children less than 12 months of age who
required hospitalization did not significantly decrease,
however [1208 (61.4 %) vs. 414 (60.6 %); p = 0.939].
Severe dehydration decreased significantly from 648/
1960 children (33.1 %) in the pre- to 117/681 children
(17.2 %) in the post-vaccine period, a 58 % reduction
(OR = 0.42, 95 % CI: 0.34–0.52; p < 0.0001). The number
of children with severe RVAGE decreased by 67 % after
introduction of Rotarix vaccine from 796/1828 children
(43.5 %) to 136/675 children (20.1 %), an unadjusted OR
of 0.33 (95 % CI: 0.27–0.40; p < 0.0001).
Measurement of the core study outcomes
Treatment outcome proportions, severe dehydrating
diarrhea, and the prevalence of RVAGE within all-cause
AGE in the pre- and post-vaccination periods were com-
pared using a generalized linear binominal model with a
probit link function controlling for all possible predic-
tors. The analysis showed that successful treatment out-
come was not significantly different in the two periods.
Similarly, AGE-related deaths before and after the intro-
duction of rotavirus vaccine did not differ significantly.
However, referral for intensive care was significantly less
frequent in the post-vaccine period (Tables 2 and 3).
Severe dehydrating diarrhea, and the overall prevalence
of RV antigen-positive, showed statistically significant
reductions approaching 50 and 48 % in 2013–2014,
respectively (Table 3).
RVAGE
Our study showed that there was a significant 48 %
decrease in the prevalence of RVAGE in the post-vaccine
period (Table 3). In the post-vaccine period, the propor-
tion of children under 12 months of age with RVAGE
(57.1 %, 133/233) was also significantly reduced when
compared with the pre-vaccine period (65.6 %, 1002/1528)
giving an OR of 0.718 (95 % CI: 0.543–0.949; P = 0.004).
The median annual number of RVAGE hospitalizations
was 194 in the pre-vaccine period compared with 68 in
2013–2014, a 65 % reduction (95 % CI: 58–71). The num-
ber of emergency unit visits decreased by 58 % in the
post-vaccine period to 28.8 % (67/233) compared with
44 % (672/1528) during the pre-vaccine period, an OR of
0.42 (95 % CI: 0.323–0.533); p = 0.0001). Among those
hospitalized with severe RVAGE, severe dehydration was
also significantly reduced from 34.7 % (276/795) before
vaccination to 19.3 % (26/135) in 2013–2014, an OR of
0.45 (95 % CI: 0.29–0.71; p < 0.0001). In contrast, the pro-
portions of all non-RV AGE patients, patients who were
hospitalized, and/or attended the emergency room were
all significantly greater in 2013–2014 compared with the
pre-vaccine period. For all non-RV AGE patients, the pro-
portions were 80.1 % (940/1173) and 59.4 % (2239/3767),
Fig. 1 Monthly variation of RV + ve & RV –ve AGE: Pre and Post vaccination periods
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an OR of 2.8 (95 % CI: 2.4–3.2). For hospitalized patients,
they were 79.9 % (539/675) and 56.5 % (1032/1828), an
OR of 3.1 (95 % CI: (2.5–3.8), and for emergency unit
visits they were 81.3 % (292/359) and 60.8 % (1041/1713),
an OR of 2.8 (95 % CI: 2.1–3.7).
Prevalence and genotype distributions of circulating
rotavirus strains
Genotyping was available for 80 pre-vaccination and 48
post-vaccination RV strains (Table 4). The majority—74/80
of the pre-vaccination strains (83 %) and 40/48 post-
vaccination strains (92.5 %)—were isolated from children
less than 24 months of age. The most prevalent G types in
the pre-vaccination period were G1 (33/80, 41.3 %) and G2
(34/48, 42.5 %). The percentage of G1 did not change in
the post-vaccine period (16/48, 33.3 %) but G2 was dramat-
ically reduced (2/48, 4.2 %). G9 increased from 5/80 strains
(6.3 %) before, to 14/48 strains (29.2 %) after, RV vaccine
introduction. P genotypes showed similar variation, with
P[4] accounting for 33.8 % of the pre-vaccination strains,
but became less frequent, comprising 14.3 % of the post-
vaccine strains. P[8] strains increased in frequency from
26.3 to 51 % after Rotarix introduction. We observed in-
creasing frequencies of mixed G and P genotypes circulat-
ing in the post-vaccine period that had previously been
extremely uncommon. These included G1G3, G2G9, and
G3G9, accounting for 20.8 % (10/48) and P[4]P[8],
P[6]P[8], and P[8]P[10], accounting for 22.9 % (11/48) of
the post-vaccine strains. These genotypes accounted for
only 6.3 % (5/80, all G1G2), and 7.5 % (6/80, all P[4]P[8]) of
pre-vaccination strains. The prevalence of G–P combina-
tions also changed following introduction of the RV vac-
cine. G1P[8] increased in frequency from 45.5 % (15/33) to
87.5 % (14/16), while G2P[4] decreased from a frequency of
76.5 % (26/34) to the detection in only two strains after
Rotarix introduction. We also observed G9P[8] and G9P[4]
strains that were not detected in the pre-vaccine period,
but which became more prevalent in 2013–2014 and
accounted for 57 % (8/14) and 14 % (2/14), respectively
(Table 4).
Table 2 Baseline characteristics: all-cause acute gastroenteritis: pre and post rotavirus vaccine introduction
Variable No(%) Pre-vaccine period Post-vaccine period OR (95 % CI) P value
N = 3973 n = 1182 (post-vaccine cohort)
Age group
< 12 months 2476(62.3) 694(58.7) 0.87(0.76–0.99) 0.042
12–23 month 1042(26.2) 310 (26.2) 0.99(0.86–1.15 0.887
> 23 months 455(11.5 178 (15.1 1.35(1.12–1.63) 0.001
Females 1557 (39.2) 449 (38.0) 0.96(0.87–1.07) 0.456
Males 2416 (60.8) 733 (62.0)
Vomiting 3495(88.0) 1101 (93.1) 1.65(1.34–2.04) <0.0001
Febrile 2528(63.6) 533(45.1) 0.56(0.51–0.62) <0.0001
Age (months)
Mean(SD) 11.74(9.44) 12.93(11.20) 0.001
Duration of symptoms days
Mean(SD) 2.98(1.67) 3.33(1.58) <0.0001
Diarrhea episodes/day
Mean(SD) 6.77(4.34) 5.57(3.41) <0.0001
Diarrhea duration(days):
Mean (SD) 3.02(2.12) 3.40(1.89) <0.0001
Hospital treatment (days)
Mean (SD) 2.23(1.67) 2.09(2.44) 0.690
Severe dehydration 848/3902 (21.7) 168/1144 (14.7) 0.641(0.535–0.767) <0.0001
Rotavirus gastroenteritis 1528/3676 (41.6) 233/1173 (19.9) 0.45(0.38–0.51) <0.0001
Treatment outcome N = 3899 N = 1161
Successful treatment 3547(91.0) 957(82.4) 0.0001
Deaths 27(0.7) 13(1.1) 0.177
Referred for intensive care 60 (1.5) 8(0.7) 0.037
Not known 265(6.8) 183(15.8) 0.0001
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Discussion
Diarrhea remains a major cause of child morbidity and
death mostly in low-income countries including Yemen.
Rotavirus is the primary cause of severe dehydrating
diarrhea in children under 5 years of age. The health
and economic burdens are substantial, affecting already
overcrowded emergency rooms and hospital inpatient
facilities in addition to increasing the financial stresses
on poor parents [11, 12].
Following the introduction of RV vaccine, impressive
declines in RV and all-cause diarrhea hospitalizations
were observed in many countries [13]. This study of the
epidemiology of all-cause and rotavirus-specific diarrhea
hospitalization is the first to report that rotavirus vaccine
Table 3 Core study outcomes during pre & post-RV vaccination periods: binominal generalized linear models with probit link
function
Pre & Post vaccination Unadjusted Exponential (B) Adjusted Exponential(B)b
Periods N(%) (95 % Wald CI)a P (95 % Wald CI)a P
Treatment outcome
Successfully treated
Pre: 3547/3899 (90.9) 1 1
Post: 957/1161 (82.4) 0.640 (0.569–0.720) 0.0001 0.995 (0.808–1.227) 0.964
Referred for intensive care
Pre: 60/3899 (1.5) 1 1
Post: 8/1161 (0.7) 0.442 (0.295–0.660) 0.0001 0.615 (0.400–0.946) 0.027
Deaths
Pre 27/3899(0.7) 1 1
Post 13/1161 (1.12) 0.801 (0.526 -1.219) 0.299 0.772 (0.478–1.248) 0.291
Severe dehydrating diarrhea
Pre: 848/3902 (21.7) 1 1
Post: 168/1144 (14.7) 0.64 (0.54–0.77) 0.0001 0.501 (0.416–0.602) 0.0001
Rotavirus gastroenteritis
Pre: 1528/3676 (41.6) 1 1
Post: 233/1173 (19.9) 0.45 (0.38–0.51) 0.0001 0.523 (0.476–0.574) 0.0001
aConfidence Interval
bAdjusted for age group, gender, hospital site, symptoms duration(days), and diarrhea episodes duration(days)
Table 4 Prevalence of rotavirus strains before and after rotavirus vaccine introduction
Rotavirus strain Post vaccination Pre vaccination % Proportion difference(95 % CI) P value
No(%) No(%)
Total strains 48 80
G1 16(33.3) 33(41.3) −7.92 % (−25.1; 9.2) 0.366
G2 2(4.17) 34(42.5) −38.33 % (−50.6; −26.1) <0.0001
G9 14(29.2) 5 (6.3) 22.9 % (9.0; 36.8) 0.001
G mixa 10(20.8) 5 (6.3) 14.6 % (2.0; 27.4) 0.013
P[4] 7(14.6) 27(33.8) −19.2 % (−33.6; −4.8) 0.009
P[8] 25 (52.1) 21(26.3) 25.8 % (8.7; 42.9) 0.003
P{mix]b 11(22.9) 6(7.5) 15.4 % (2.2; 28.6) 0.013
G-P combination
G1P[8] 14/16(87.5 %) 15/33(45.5 %) 42.0 % (18.6; 65.5) <0.0001
G2P[4] 2/2 (100) 26/34(76.5 %) 23.5 (9.3; 37.8) 0.001
G9P[8] 8/14(57.1) 0 -
G9P[4] 2/14 (14.3) 0 -
G mixa, G1G3;G2G9;G3G9, G1G2
P [mix]b, P[4]P[8];P[6]P[8];P[8]P[10], P[4]P[8]
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introduction in Yemen may have resulted in important
epidemiological changes in infant and childhood diar-
rhea. The study showed an impressive 50 % reduction in
all-cause severe dehydrating diarrhea and a statistically
significant reduction of rotavirus diarrhea by 48 % in the
post-vaccine period (Table 3). After Rotarix vaccine
introduction, the prevalence of RVAGE was also signifi-
cantly reduced in children <12 months of age, who are
the most vulnerable (Table 2). Our study also showed
that among all children with severe all-cause GE that
needed hospitalization, severe RVAGE hospitalization
was significantly reduced by 67 % from 43.5 % (796/
1828) to 20.1 % (136/675), an OR of 0.33 (95 % CI:
0.27–0.403; p < 0.0001) after Rotarix vaccine introduced
in Yemen. There was also a significant reduction of 49 %
of RVAGE patients visiting the emergency room from
44 % (672/1528) to 28.8 % (67/233), an OR of 0.51
(0.38–0.69; p < 0.0001). Despite successful treatment out-
come remained unchanged in the pre- and postvaccine
periods, we observed a statistically significant reduction
with an adjusted OR of 0.615 (95 % CI: 0.400–0.946) of
children referred for further intensive care in the post-
vaccine period (Table 3). These results suggest reductions
in both RV mortality and in the cost of hospitalization
may have occurred. Previous reviews of RV vaccine and
diarrhea mortality included efficacy studies that showed
regional variation, with 91 % prevention of severe RV diar-
rhea in developed countries, but efficacy as low as 42.2 %
in high-mortality countries. The evidence provided by
these efficacy studies suggests that RV vaccine has de-
creased RV-specific and all-cause diarrhea mortality in all
regions of the world [14, 15]. In GAVI-eligible countries,
including Yemen—one of world’s poorest countries—RV
vaccine could prevent an estimated 2.46 million childhood
deaths between 2011 and 2030, with an annual decrease
of 180,000 at peak vaccine uptake [16].
Rotavirus is most frequently associated with severe
dehydrating diarrhea, substantial hospitalization, in-
creased emergency room visits, and increased costs
for both hospitals and parents [12]. In this study, in
addition to greater than 60 and 49 % reductions of
severe RVAGE hospitalization and emergency room
visits, respectively, we also observed significant reduc-
tions in severe dehydration among severe all-cause
and severe RAVGE inpatients. Both showed significant
reductions of 58 % from 33.1 % (648/1960) to 17.2 %
(117/681), an OR of 0.42 (95 % CI 0.34–0.52), and
55 % from 34.7 % (276/795) to 19.3 % (26/135), an
OR of 0.45 (95 % CI: 0.29–0.71), respectively. The
introduction of RV vaccine in Yemen opened a new
era of vaccine-based intervention for diarrhea control
with extensive health and economic benefits. The
monitoring of changes in the burden of RV and all-
cause diarrhea provides important information to
assist health policy-makers in Yemen and neighboring
poor countries in the horn of Africa.
Following the introduction of RV vaccine, we observed
an important and significant increase in the proportion of
children with non-RV AGE at the sentinel hospitals as
RVAGE prevalence significantly decreased. We observed
an overall increase in the proportion of hospital visits for
non-RV AGE to 80.1 % (940/1173) from 59.4 % (2239/
3767) in the prevaccine period. Emergency room visits for
non-RV AGE increased to 81.3 % (292/359) from 60.8 %
(1041/1713), and hospitalization for severe nonRV AGE
increased to 79.9 % (539/675) from 56.5 % (1032/1828). A
recent study from Nicaragua reported that norovirus
(NV) was more commonly detected as a cause of diarrhea
while rotavirus became less common following rotavirus
vaccine introduction [17]. The study reported that more
than 57 % of diarrhea in children under 24 months of age
was caused by NV. Another study reported that NV has
become the leading viral cause of gastroenteritis in both
hospital and community settings in Nicaragua following
the implementation of RV vaccination [18]. In Yemen
before rotavirus vaccine introduction, NV was detected in
10 % of children from 1 to 60 months of age with AGE
[8]. To establish effective management guidelines, epi-
demiological changes in the causes of childhood diarrhea
following introduction of rotavirus vaccine need ongoing
surveillance. Our findings of increasing non-RV severe GE
could indicate that NV may be increasing and needs close
monitoring. Additional preventive interventions that
reduce the burden of diarrhea-related morbidity and mor-
tality need consideration. These include promotion of
breastfeeding, provision of safe water, and improving sani-
tation and hygiene in low-income countries, including
Yemen, and particularly in communities with poor socio-
economic status.
Worldwide, the most common G genotypes reported
are G1, G2, G3, and G9; P[4] and P[8] are the common
P genotypes [19, 20]. Before rotavirus vaccine introduc-
tion, five G–P combinations: G1P[8], G2P[4], G3P[8],
G4P[8], G9P[8] accounted for almost 90 % of rotavirus
disease in children worldwide [20]. The only study in
Yemen before rotavirus vaccine introduction reported
that 55 % of the G–P strains were G1P[8], 21 % were
G9P[8], and 12 % were G2P[4], but the study was limited
by its restriction to one city (Sana’a) in the highlands. In
our study, which was conducted in two cities (Taiz,
located at an altitude of 1400 m, and Aden, a coastal
city) included surveillance data from a 5-year prevaccine
period. We observed that the most prevalent strains
were G1P[8], isolated from 15/33 patients (45.5 %), and
G2P[4], isolated from 26/34 patients (76.5 %). The
G9P[8] strain had not been detected before Rotarix
introduction, which may indicate temporal and geo-
graphical variations [21].
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Many low-income countries in addition to Yemen have
added rotavirus vaccine to their national immunization
programs. Monitoring vaccine effectiveness against the
circulating rotavirus strains and any accompanying
changes in strain diversity need continuous active rota-
virus surveillance. It is crucial to identify rotavirus strain
diversity. Our study revealed a statistically significant
38.3 % (95 % CI: −50.6; −26.1) reduction of G2 (hetero-
typic) circulating strains in the post-vaccine period even
though they are not included in the monovalent G1P[8]
vaccine. The G1 strain (partly homotypic) decreased to
33.3 % (16/48) from 41.3 % (33/80), a nonsignificant
reduction of 7.9 % (Table 4). Additionally, G9 strains sig-
nificantly increased in the post-vaccine period, with the
emergence of G9P[8] and G9P[4], which were not
detected in RV from the pre-vaccine period (Table 4).
These findings may indicate that variations in circulating
rotavirus strains can occur independently and not as a
result of rotavirus vaccine selective pressure. Existing evi-
dence confirms that Rotarix provides good protection
against both fully and partly homotypic, and fully hetero-
typic circulating strains including G2P[4], G9P[4], and
G9P[8] [22–24]. A recent systematic review and meta-
analysis of published research reports on the distribution
of rotavirus strains and strain-specific rotavirus vaccine ef-
fectiveness in high- and middle-income Latin America
countries showed that rotavirus vaccines (RV1 and RV5)
provided adequate protection against RV disease, and that
the protection was effective against various homotypic,
partly heterotypic, and fully heterotypic rotavirus strains.
The review also confirmed that vaccine-induced selective
pressure had not occurred. The authors acknowledged the
lack of data from low-income countries [25]. A previous
study conducted in a low-income setting in Chiapas, the
poorest state in Mexico, showed that Rotarix provided ad-
equate protection against severe RVAGE caused by a fully
heterotypic strain (G9P[4]), and reported a vaccine effect-
iveness of 94 % [24]. These findings are reassuring for
low-income countries that have recently introduced rota-
virus vaccines.
In our study, we observed increase in the prevalence
of mixed G and [P] circulating strains after Rotarix vac-
cine introduction. The G-mix prevalence increased to
20.8 % and [P] mix to 22.9 % (Table 4). Similar observa-
tions were reported in a study from Bangladesh [26] that
reported a substantial proportion of mixed rotavirus cir-
culating strains of more than 14 %, and exceeding 37 %
in 2009–2010 that could have resulted in the generation
of unusual combined G[P] circulating strains in 2011–
2012. Similar observations have been reported in other
countries in the Indian subcontinent [27].
The study has several limitations. It was conducted
based on surveillance data collected from two sentinel
hospitals, which are not devoid of problems such as
missing data. Other limitations are the observational de-
sign, and a short post-vaccine period. Lack of information
on the vaccination status of children included in the sur-
veillance was a major limitation. The treatment outcomes
of 6.8 % of children in the pre-vaccine and 15.8 % in the
post-vaccine periods were not known (Table 2), and that
may have affected the result of the vaccine impact on the
treatment outcomes, particularly diarrhea-related mortal-
ity. In addition, follow-up of children with severe AGE
who were hospitalized ended on the day of discharge.
However, the proportion of children hospitalized with se-
vere all-cause or RVAGE who needed referral for intensive
care was significantly reduced (by 38 %) in 2013–2014
(Tables 2 and 3). Finally, the surveillance data were from
two governorates, Taiz and Aden, and may not be directly
applicable to settings in other governorates of Yemen.
However the results provide an important indication of
the potential benefits of rotavirus vaccine in other regions
of Yemen and the neighboring low-income countries in
the horn of Africa because these countries and Yemen
have high levels of poverty and high infant and childhood
mortality rates.
Conclusions
This study showed that the introduction of rotavirus
vaccine in Yemen significantly reduced both all-cause
and RVAGE hospitalization. The proportion of children
who were severely dehydrated was also significantly re-
duced. The prevalence of severe RVAGE was signifi-
cantly reduced in the post-vaccine period and the
seasonal pattern became blunted and less defined with
shorter duration. Significant increases in the proportions
of children at the sentinel hospitals with non-RV AGE
that occurred following RV vaccine introduction may be
at least partly due to increasing prevalence of norovirus
(NV) AGE.
Scaling-up interventions such as promotion of breast-
feeding, improving sanitation facilities, providing a safe
water supply, and improved hygiene, including hand
washing, are important especially in poor communities
to reduce the unexpected rise of non-RV AGE.
Rotavirus circulating strains in the post-vaccine period
showed increases in the G and [P] mix strains of more
than 20 % each, while G9P[8] and G9P[4] that were not
detected in the pre-vaccine period became more preva-
lent in 2013–2014. Monitoring of rotavirus circulating
strains and NV in the post-vaccine era is crucial to set
new guidelines to reduce the burden of childhood
diarrhea-related mortality and morbidity.
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